Growth Metrics

Gilead Sciences (GILD) Share-based Compensation (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -5.22%
Dec 31, 2025 0.00%
Sep 30, 2025 2.22%
Jun 30, 2025 7.66%
Mar 31, 2025 -5.86%
Dec 31, 2024 2.78%
Sep 30, 2024 2.86%
Jun 30, 2024 12.30%
Mar 31, 2024 -6.97%
Dec 31, 2023 -0.50%
Sep 30, 2023 2.02%
Jun 30, 2023 20.00%
Mar 31, 2023 -5.17%
Dec 31, 2022 3.57%
Sep 30, 2022 1.82%
Jun 30, 2022 26.92%
Mar 31, 2022 -18.24%
Dec 31, 2021 -7.02%
Sep 30, 2021 3.01%
Jun 30, 2021 19.42%
Mar 31, 2021 -13.66%
Dec 31, 2020 -6.94%
Sep 30, 2020 20.14%
Jun 30, 2020 2.13%
Mar 31, 2020 -10.19%
Dec 31, 2019 -3.09%
Sep 30, 2019 -6.90%
Jun 30, 2019 21.68%
Mar 31, 2019 -18.29%
Dec 31, 2018 -11.62%
Sep 30, 2018 -21.43%
Jun 30, 2018 14.55%
Mar 31, 2018 -34.13%
Dec 31, 2017 195.58%
Sep 30, 2017 10.78%
Jun 30, 2017 14.61%
Mar 31, 2017 -12.75%
Dec 31, 2016 7.37%
Sep 30, 2016 0.00%
Jun 30, 2016 7.95%
Mar 31, 2016 -9.28%
Dec 31, 2015 0.00%
Sep 30, 2015 1.04%
Jun 30, 2015 4.35%
Mar 31, 2015 -3.16%
Dec 31, 2014 -5.00%
Sep 30, 2014 20.48%
Jun 30, 2014 1.22%
Mar 31, 2014 14.35%
Dec 31, 2013 14.60%
Sep 30, 2013 11.83%
Jun 30, 2013 -9.41%
Mar 31, 2013 7.60%
Dec 31, 2012 5.39%
Sep 30, 2012 12.52%
Jun 30, 2012 -0.67%
Mar 31, 2012 4.57%
Dec 31, 2011 0.92%
Sep 30, 2011 -7.87%
Jun 30, 2011 1.32%
Mar 31, 2011 -7.27%
Dec 31, 2010 2.99%
Sep 30, 2010 7.82%
Jun 30, 2010 2.57%
Mar 31, 2010 12.00%
Dec 31, 2009 -3.93%
Sep 30, 2009 8.94%
Jun 30, 2009 -2.64%